Q-omics provides the consensus-scored ZFYVE9 profile across patient tissues and cancer cell-line models. ZFYVE9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZFYVE9 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, ZFYVE9 RNA expression shows 20,806 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where ZFYVE9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFYVE9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFYVE9 survival associations across molecular data types. ZFYVE9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFYVE9 RNA expression–survival associations across cancer types. High ZFYVE9 expression shows unfavorable associations in ACC, SARC and BLCA, but favorable associations in KIRC, SCLC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZFYVE9 RNA expression.
This table summarizes ZFYVE9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZFYVE9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFYVE9 shows lower tumor expression in KICH, THCA, LUAD, KIRP and KIRC and higher tumor expression in HNSC. The KICH box plot shows higher ZFYVE9 RNA expression in normal versus tumor tissue (log2 FC = −1.228, t-test p < 0.001).
This table shows molecular features associated with ZFYVE9 in patient tissues and cancer cell lines. In patient samples, ZFYVE9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFYVE9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
